What is BioAdaptives Inc. (BDPT) stock price today?

BioAdaptives Inc. (BDPT) is currently trading at $0.00.

What is BDPT P/E ratio?

BioAdaptives Inc.'s P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BDPT return on equity (ROE)?

BioAdaptives Inc.'s return on equity (ROE) is 100.00%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is BioAdaptives Inc.'s market cap?

BioAdaptives Inc. has a market capitalization of $28461.

OTC · Packaged Foods

BioAdaptives Inc. (BDPT) Stock

$0.00 OTC: BDPT Consumer Defensive

BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals.

Valuation

Metric	Value
Price	$0.00
Market Cap	$28461
P/E Ratio	-0.02
P/B Ratio	-0.01
P/S Ratio	1.16
EPS (TTM)	$-0.14
52-Week High	$0.07
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	100.00%
ROA	-502.87%
ROCE	46.33%
Gross Margin	69.81%
Operating Margin	-3594.81%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	0.05

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-1.0M	$0	$0	$-1.0M	$-1.0M
Net Profit	$-1.0M	$-1.0M	$-1.0M	$-1.0M	$-2.0M
EPS	$-4.67	$-1.27	$-0.12	$-0.11	$-0.15
Op Margin	-3216.0%	-2456.9%	-801.7%	-4751.8%	-5701.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$0	$0	$0	$0	$0
Total Liabilities	$1.0M	$1.0M	$2.0M	$2.0M	$2.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$0	$0	$0

Latest News

BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform ACCESS Newswire · Jul 29, 2026 BioAdaptives Completes Commercial Supply Chain Ahead of MyndSystem and Xcellara Launches InvestorsHub · Jul 23, 2026 BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches GlobeNewswire · Jul 23, 2026 BioAdaptives Outlines Xcellara Platform Strategy Ahead of XcellaraHeart Launch InvestorsHub · Jul 16, 2026 BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness GlobeNewswire · Jul 16, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$0	$0	$0	$0	$-1.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$0	$0	$0	$0	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.33
FCF Yield	-1830.43%
Quick Ratio	0.04
Interest Coverage	-6.64
Return 1Y	-89.55%
Return 3Y	-98.98%
Return 5Y	-99.96%

Ownership

Insiders Held0.15%

Institutions Held0.00%

Institutions Float Held0.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AJYGAJ1G, Inc.	$0.04	+12.32%	401.00	$401890	0.00%
BSFCBlue Star Foods Corp.	$0.00	—	-0.01	$16674	0.00%
DEWMDewmar International BMC, Inc.	$0.00	—	-3.18	$354501	0.00%
DMANDemand Brands, Inc.	$0.00	—	2.00	$394330	0.00%
HSEEFHill Street Beverage Company Inc.	$0.01	+0.00%	-0.03	$36111	0.00%

About BioAdaptives Inc.

BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a medical device; and Xcellara, PawPa, and MyndMed. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. The company was incorporated in 2013 and is based in Las Vegas, Nevada.

BioAdaptives Inc. (BDPT) stock trades at $0.00 with a market capitalization of $28461. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.01, price-to-sales of 1.16. Over the past 52 weeks the stock has ranged between $0.00 and $0.07, and currently trades 100.0% below its 52-week high.

On profitability, BioAdaptives Inc. generates a return on equity (ROE) of 100.00% — well above the market average, a sign of a high-quality business, return on capital employed of 46.33%, an operating margin of -3594.81%, a net profit margin of 0.00%.

Official website: www.bioadaptives.com